Demonstrations that LTS-201 results in deep, dose-dependent MSH3 mRNA KD, ranging from 48% to 94%, in >90% of MSNs in nonhuman primates. Preclinical validation that LTS-201-mediated MSH3 KD results in ...
Pharmaceutical Technology on MSN
Formation Bio launches $600m drug development fund
Formation Bio plans to source Phase I and Phase II assets from biotechnology and pharmaceutical companies.
Axios AI+ on MSN
Exclusive: OpenAI has acquired Orchestra Bio
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ...
Reflector Bio, founded by MIT-trained computational biologist and early employee at Flagship Pioneering's Cellarity, Yuge Ji, ...
A simulation study reports that a bio-inspired, AI-enabled wireless sensor network design improved network lifetime, energy ...
Chicago-based financial-services firm details how machine learning, multi-factor modeling and cross-border risk ...
OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .
OpenAI has acquired Orchestra Bio, a company building software to coordinate complex drug development work. The deal, ...
Researchers show that lexical and embedding-based drift measures between synthetic and real clinical text moderately predict ...
OpenAI has acquired Orchestra Bio, a company whose platform coordinates drug development work across biopharma teams, and is ...
ChatGPT maker OpenAI is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite of products.
NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome ("GI-ARS"), after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results